Werewolf Therapeutics (HOWL)
(Delayed Data from NSDQ)
$1.49 USD
+0.04 (2.76%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $1.47 -0.02 (-1.34%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
HOWL 1.49 +0.04(2.76%)
Will HOWL be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for HOWL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HOWL
Werewolf Therapeutics, Inc. (HOWL) Just Flashed Golden Cross Signal: Do You Buy?
XOMA Royalty (XOMA) Q2 Earnings and Revenues Surpass Estimates
HOWL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Beyond Air, Inc. (XAIR) Reports Q1 Loss, Lags Revenue Estimates
CorMedix (CRMD) Surpasses Q2 Earnings and Revenue Estimates
Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know
Other News for HOWL
180 Bullish Setup appears for HOWL after 2.76% move
Is HOWL building bullish momentum? Pocket Pivot shows up after advancing 3.57%
Bollinger Band Squeeze appears for HOWL after 3.45% move
H.C. Wainwright Sticks to Its Buy Rating for Werewolf Therapeutics (HOWL)
HOWL forms 180 Bullish Setup on September 16